ArticleJournal for immunotherapy of cancer2026
Targeting VEGF signaling and stromal remodeling enhances chemoimmunotherapy efficacy in esophageal cancer.
Article in Journal for immunotherapy of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeoadjuvant chemoimmunotherapy (NACI) has shown promising results in treating esophageal squamous cell carcinoma (ESCC), yet the mechanisms driving its efficacy remain poorly defined, limiting further optimization of this regimen.
methodsTo investigate the dynamics of the tumor microenvironment (TME), we integrated single-cell RNA sequencing, immunorepertoire profiling, and spatial transcriptomics across 18 samples from nine patients with ESCC undergoing NACI. Computational workflows encompassed integrated clustering, gene set enrichment, T cell receptor repertoire characterization, copy number variation estimation, and cell-cell communication inference. Spatial mapping was performed using cytoSPACE. Key findings were validated via orthogonal spatial transcriptomics, multiplex immunohistochemistry, and in vivo preclinical models.
resultsWe identified distinct post-treatment accumulation of ACKR1+ endothelial cells (ECs) and CFD+ cancer-associated fibroblasts (CAFs) at tumor boundaries, potentially correlating with enhanced CD8+ T cell infiltration and improved clinical outcomes. Conversely, treatment-resistant tumors exhibited VEGFA-driven upregulation in malignant cells, promoting RGCC+ ECs with elevated VEGFR2 expression. These RGCC+ ECs synergized with MMP11+ CAFs to form a collagen-rich tumor niche that fostered malignancy and immunosuppression. Importantly, targeting VEGFR2 not only improved therapeutic response but also reversed immune suppression.
conclusionsThis study reveals that stromal cells such as CAFs and ECs within the TME collaboratively determine NACI efficacy in ESCC. These findings could offer novel theoretical insights and actionable strategies for enhancing treatment efficacy in ESCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.